Required fields are marked with *

Verification code

SARS-CoV

CAS No. Product Name Inquiry
2599039-61-7
Crexavibart
2640223-84-1
Masavibart
2640224-48-0
Nepuvibart
2641299-75-2
RdRP-IN-3
RdRP-IN-3 is a small molecule inhibitor targeting the RNA-dependent RNA polymerase (RdRP) enzyme, which is essential for the replication of RNA viruses. By inhibiting RdRP, RdRP-IN-3 disrupts the viral replication process, potentially reducing the viral load and alleviating the severity of infections caused by RNA viruses. This makes RdRP-IN-3 a candidate for antiviral therapy against diseases caused by such viruses, offering a strategic approach to managing viral infections and improving treatment outcomes.
2647441-36-7
Obeldesivir
Obeldesivir is an oral prodrug of the parent nucleoside GS-441524, which targets the highly conserved RNA-dependent viral RNA polymerase (RdRp).
2647442-13-3
GS-621763
GS-621763 is an orally bioavailable prodrug of GS-441524. The nucleoside metabolite of remdesivir, GS-441524 displays potent anti-SARS-CoV-2 efficacy, and is being evaluated in clinical as an oral antiviral therapeutic for COVID-19.
2647530-73-0
Ensitrelvir
Ensitrelvir (S-217622) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM).
2648089-95-4
AT-9010 triethylamine
The active triphosphate metabolite AT-9010 can inhibit SARS-CoV-2 replication.
2657659-42-0
Jun9-72-2
2679814-93-6
SARS-CoV-2 Mpro-IN-14
2682897-84-1
SARS-CoV-2-IN-68
2698336-82-0
Antiviral agent 5
An intermediate in the numerous antiviral protease inhibitors is the glutamine analogue. Antiviral agent 5 is an intermediate used in antiviral agents targeting 3C and 3CL proteases including SARS-CoV-2 Mpro.
2708270-99-7
SIMR3030
2708934-53-4
CCF0058981
CCF0058981, a non-covalent SARS-CoV-2 3CLpro (SC2) inhibitor (IC50 = 68 nM), can inhibit SARS-CoV-1 3CLpro (SC1) with an IC50 of 19 nM. It has antiviral efficacy and has the potential to study COVID-19.
2710278-53-6
SARS-CoV-2-IN-22
SARS-CoV-2-IN-22 is a SARS-CoV-2 pseudovirus entry inhibitor with an IC50 value of 16.96 µM. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals.
2712126-48-0
Imiquimod-d9
Imiquimod-d9 (R 837-d9) is the deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.
2713437-86-4
Pomotrelvir
2719679-31-7
MMT5-14
MMT5-14 is a remdesivir analogue with a higher antiviral activity in four variants of SARS-CoV-2 than Remdesivir (HY-104077).
2721455-52-1
SARS-CoV-2-IN-12
SARS-CoV-2-IN-12 (Compound 27) is a potent SARS-CoV-2-related 3C-like protease inhibitor (Ki=32.1 pM) for preventing SARS-CoV-2 viral replication and that could be useful in the research of COVID-19. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals.
2722634-95-7
SARS-CoV-2-IN-10
SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication. SARS-CoV-2-IN-10 may be a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease.

※ Please kindly note that our services are for research use only.

Copyright © 2024 BOC Sciences. All rights reserved.